The role of artificial intelligence (AI) in healthcare took a leap forward in 2024 when the Nobel Prize in Chemistry was awarded to scientists including Demis Hassabis for their work on AlphaFold, a programme heralded as a solution to the 鈥�50-year-old problem of protein structure prediction鈥�.
At the Financial Times (FT) Pharma and Biotech Summit in London on 6 November, Hassabis, CEO and co-founder of Google DeepMind and Isomorphic Labs, shared his insights on the role of AI in healthcare and its future potential. Hassabis believes that AI could have an even greater impact on society than the internet or mobile technology, comparing it to an 鈥渆lectricity or fire kind of impact鈥�.
Building on his success with AlphaFold, Hassabis founded Isomorphic in 2021, a digital biology company that uses AI for drug discovery. Isomorphic鈥檚 strategy focuses on algorithmic innovation rather than building wet labs, as Hassabis believes there is 鈥渟till a lot of juice to be squeezed鈥� from existing data sources through advanced techniques like synthetic data generation.
According to a , AI is considered the most disruptive technology among businesses, including in the healthcare industry. Hassabis emphasised AI鈥檚 value in this field: 鈥淚 can’t think of a better use case than using AI to try and find cures, to help celebrate finding cures to terrible diseases. What would be a better, more beneficial use of AI?鈥� he asked.
GlobalData is the parent company of 色界吧 Technology.
In 2024, Isomorphic secured high-profile collaborations with pharma giants Eli Lilly and Novartis, totalling $1.7bn and $1.2bn respectively. Though Hassabis kept specific project details under wraps, he said that 鈥渢hey are going extremely well鈥�.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHowever, Hassabis also acknowledged the potential existential risks posed by advanced AI systems and underscored the need for research, evaluation, and regulatory frameworks to address them. 鈥淚 think it needs to be taken very seriously and treated a lot more humility and respect that I think this kind of technology deserves,鈥� he said.
He urged collaboration among governments, civil society, and academia to develop testing protocols and guardrails, saying: 鈥淭here are so many unknowns about it, and I think we need a lot more research on that, and we’re trying to do that.鈥�
When describing his overall stance on AI, Hassabis described himself as 鈥渁 cautious optimist.鈥� He explained: 鈥淚’m optimistic that we’ll get this right, as long as we approach it in the right way, actually, using the scientific method and trying to be very thoughtful about each step that we take as a vehicle.鈥�
Looking forward to the future, Hassabis shared his ambitious vision: 鈥淢y dream is to eventually have virtual cells, like a simulation of a virtual cell. We鈥檙e maybe ten years away from that,鈥� he concluded.
